Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma

European Journal of Cancer

Volumn 46, Issue 2, 2010, Pages 420-429

  Moschetta, Michele ^a   Di Pietro, Giulia ^a   Ria, Roberto ^a   Gnoni, Antonio ^a   Mangialardi, Giuseppe ^a   Guarini, Attilio ^b   Ditonno, Paolo ^c   Musto, Pellegrino ^d   D'Auria, Fiorella ^d   Ricciardi, Maria Rosaria ^e   Dammacco, Franco ^a   Ribatti, Domenico ^a   Vacca, Angelo ^a  

^a UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^c DI VENERE HOSPITAL   (Italy)

^d REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiogenesis; Bortezomib; Macrophages; Multiple myeloma; Vasculogenesis; Zoledronic acid

Indexed keywords

BASIC FIBROBLAST GROWTH FACTOR; BORTEZOMIB; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; VASCULOTROPIN; ZOLEDRONIC ACID;

ADULT; AGED; ANGIOGENESIS; ARTICLE; BONE MARROW; CELL ADHESION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; MACROPHAGE; MALE; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; DIPHOSPHONATES; DRUG SYNERGISM; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; IMIDAZOLES; MACROPHAGES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PHOSPHORYLATION; PYRAZINES; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 72449165023     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.10.019     Document Type: Article

References (41)

1. Kyle R.A., and Rajkumar S.V. Multiple myeloma. New Engl J Med 351 18 (2004) 1860-1873
2. Ribatti D., Nico B., and Vacca A. Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma. Oncogene 25 31 (2006) 4257-4266
3. Ribatti D, Vacca A. The role of monocytes-macrophages in vasculogenesis in multiple myeloma. Leukemia 2009.
4. Scavelli C., Nico B., Cirulli T., et al. Vasculogenic mimicry by bone marrow macrophages in patients with multiple myeloma. Oncogene 27 5 (2008) 663-674
5. Sun X.F., and Zhang H. NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol 22 12 (2007) 1387-1398
6. Sarkar F.H., and Li Y. NF-kappaB: a potential target for cancer chemoprevention and therapy. Front Biosci 13 (2008) 2950-2959
7. Podar K., Shringarpure R., Tai Y.T., et al. Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib. Cancer Res 64 20 (2004) 7500-7506
8. Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002;29(6 Suppl 21):33-42.
9. Roccaro A.M., Hideshima T., Raje N., et al. Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells. Cancer Res 66 1 (2006) 184-191
10. Scavelli C, Di Pietro G, Cirulli T, et al. Zoledronic acid affects over-angiogenic phenotype of endothelial cells in patients with multiple myeloma. Mol Cancer Ther 2007;6(12 Pt 1):3256-62.
11. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Brit J Haematol 2003;121(5):749-57.
12. Durie B.G. Staging and kinetics of multiple myeloma. Semin Oncol 13 3 (1986) 300-309
13. Chen T., Berenson J., Vescio R., et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42 11 (2002) 1228-1236
14. Vacca A., Ria R., Semeraro F., et al. Endothelial cells in the bone marrow of patients with multiple myeloma. Blood 102 9 (2003) 3340-3348
15. Coluccia A.M., Cirulli T., Neri P., et al. Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib. Blood 112 4 (2008) 1346-1356
16. Chou T.C., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22 (1984) 27-55
17. Kawasaki K., Watabe T., Sase H., et al. Ras signaling directs endothelial specification of VEGFR2+ vascular progenitor cells. J Cell Biol 181 1 (2008) 131-141
18. Hideshima T., Chauhan D., Richardson P., et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277 19 (2002) 16639-16647
19. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. New Engl J Med 348 26 (2003) 2609-2617
20. Orlowski R.Z., Voorhees P.M., Garcia R.A., et al. Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 105 8 (2005) 3058-3065
21. Palumbo A., Facon T., Sonneveld P., et al. Thalidomide for treatment of multiple myeloma: 10 years later. Blood 111 8 (2008) 3968-3977
22. Yang H.H., Vescio R., Schenkein D., and Berenson J.R. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341), velcade and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 4 2 (2003) 119-122
23. Hideshima T., Richardson P., Chauhan D., et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 61 7 (2001) 3071-3076
24. Dhillon S., and Lyseng-Williamson K.A. Zoledronic acid: a review of its use in the management of bone metastases of malignancy. Drugs 68 4 (2008) 507-534
25. Gnant M., Mlineritsch B., Schippinger W., et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. New Engl J Med 360 7 (2009) 679-691
26. Mystakidou K., Katsouda E., Parpa E., and Vlahos L. Prostate cancer presenting with normal serum PSA levels and boney metastases treated with zoledronic acid. J Pain Palliat Care Pharmacother 19 3 (2005) 41-45
27. Major P.P., Lipton A., Berenson J., and Hortobagyi G. Oral bisphosphonates: a review of clinical use in patients with bone metastases. Cancer 88 1 (2000) 6-14
28. Podar K., Richardson P.G., Hideshima T., Chauhan D., and Anderson K.C. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 20 4 (2007) 597-612
29. Podar K., and Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 105 4 (2005) 1383-1395
30. Vacca A., Ria R., Ribatti D., et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 88 2 (2003) 176-185
31. Raikkonen J, Crockett JC, Rogers MJ, Monkkonen H, Auriola S, Monkkonen J. Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro. Brit J Pharmacol 2009.
32. Dunford J.E., Kwaasi A.A., Rogers M.J., et al. Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase. J Med Chem 51 7 (2008) 2187-2195
33. Clezardin P., Ebetino F.H., and Fournier P.G. Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity. Cancer Res 65 12 (2005) 4971-4974
34. Bustelo X.R., Sauzeau V., and Berenjeno I.M. GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo. Bioessays 29 4 (2007) 356-370
35. Sunwoo J.B., Chen Z., Dong G., et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 7 5 (2001) 1419-1428
36. Cusack Jr. J.C., Liu R., Houston M., et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 61 9 (2001) 3535-3540
37. Dong Q.G., Sclabas G.M., Fujioka S., et al. The function of multiple IkappaB: NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21 42 (2002) 6510-6519
38. Loercher A., Lee T.L., Ricker J.L., et al. Nuclear factor-kappaB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 64 18 (2004) 6511-6523
39. Hideshima T., Chauhan D., Hayashi T., et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22 52 (2003) 8386-8393
40. LeBlanc R., Catley L.P., Hideshima T., et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 62 17 (2002) 4996-5000
41. Pajonk F, McBride WH. The proteasome in cancer biology and treatment. Radiat Res 2001;156(5 Pt 1):447-59.